Robert J. Gould, See Remarks at Fulcrum Therapeutics, Inc. (FULC), sold 2,800 shares at $20.13 ($56K) on 2020-06-03, disclosed to the SEC on 2020-06-05.
Scheduled sale ($56k) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.13 | 1,500 | $30K | 53.7% |
| 2 | $20.04 | 1,300 | $26K | 46.3% |
| Total | $20.09 avg | 2,800 | $56K | 100% |
| Filing → |
| FULC | SELL | 2026-01-06 | $356K | — | Filing → |
| FULC | SELL | 2025-11-21 | $165K | — | Filing → |
| FULC | SELL | 2023-01-13 | $101K | — | Filing → |